Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

December 5, 2022

Study Completion Date

December 5, 2022

Conditions

COPD

Interventions

DRUG

CHF6523

CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)

Trial Locations (1)

Richmond Pharmacology, London

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT04032535 - Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects | Biotech Hunter | Biotech Hunter